Cover Image
市場調查報告書

血漿分離製劑的全球市場的預測 ∼2023年:IVIG (靜脈注射免疫球蛋白),白蛋白,第八凝血因子,von Willebrand因子,PCC (凝血素原複合體製劑),蛋白分解酵素抑制劑

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User - Global Forecast to 2023

出版商 MarketsandMarkets 商品編碼 365863
出版日期 內容資訊 英文 249 Pages
訂單完成後即時交付
價格
Back to Top
血漿分離製劑的全球市場的預測 ∼2023年:IVIG (靜脈注射免疫球蛋白),白蛋白,第八凝血因子,von Willebrand因子,PCC (凝血素原複合體製劑),蛋白分解酵素抑制劑 Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User - Global Forecast to 2023
出版日期: 2018年02月01日 內容資訊: 英文 249 Pages
簡介

全球血漿分離製劑的市場,預計2018年達212億3000萬美元,2022年達295億美元。全球規模的高齡化的發展,及免疫球蛋白的有效利用範圍的擴大,呼吸疾病患者的增加和α1抗胰蛋白酶的攝取量增加,血漿採取、分離能力的擴張等,為市場成長的主要原因。另一方面,價格高和醫療費償付額低,替代性的基因改造型產品的登場等也有妨礙市場成長的可能性。

本報告提供全球血漿分離製劑的市場調查,市場及產品概要,產業趨勢,市場成長的影響因素及市場機會分析,各產品、用途、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境與市場佔有率,主要企業簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進因素
      • 各種治療領域的免疫球蛋白的利用增加
      • 全球各國的老年人口的增加
      • 隨著呼吸疾病、AATD患者的增加,α1抗胰蛋白酶攝取量的增加
      • 血漿採取數量的增加
    • 阻礙因素
      • 成本高,和醫療費償付額的規定
      • 基因改造型的替代產品的登場
    • 市場機會
      • 血友病患者的增加
    • 課題
      • 政府的嚴格法規

第6章 產業分析

  • 簡介
  • 主要產業趨勢
    • 分離製劑的生產能力強化愈來愈受重視,和全球各國的普及
    • 血漿產品
    • SCIG (皮下注射用免疫球蛋白製劑)的利用增加
    • 有分離功能的捐血中心的增加
    • 中國的血漿產品市場成長
    • 對於基因改造因素的開發、製造,血漿分離業者的關心增加
  • 波特的五力分析
  • 供應商間比較分析

第7章 血漿分離製劑市場:各產品

  • 簡介
  • 免疫球蛋白
    • IVIG (靜脈注射免疫球蛋白,免疫球蛋白大量靜脈注射)
    • SCIG (皮下注射用免疫球蛋白製劑)
    • 其他
  • 凝血因子濃縮製劑
    • 第八凝血因子
    • 第九凝血因子
    • VWF (血友病因子)
    • PCC (凝血素原複合體製劑)
    • 纖維蛋白原濃縮物
    • 凝血因子XIII
  • 白蛋白
  • 蛋白分解酵素抑制劑
  • 其他

第8章 血漿分離製劑市場:各用途

  • 簡介
  • 神經症
  • 免疫療法
  • 血液疾病
  • 救命治療
  • 呼吸疾病
  • 血液腫瘤
  • 風濕
  • 其他的用途

第9章 血漿分離製劑市場:各終端用戶

  • 簡介
  • 醫院、診所
  • 臨床研究所
  • 教育機關

第10章 各地區分析

  • 簡介
  • 北美 (美國,加拿大)
  • 歐洲 (德國,法國,義大利,西班牙,英國等)
  • 亞太地區 (中國,日本,印度,馬來西亞等)
  • 南美
  • 中東、非洲

第11章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢
    • 事業擴張
    • 新產品的投入
    • 企業收購
    • 協定,事業合作、聯盟,合資企業

第12章 企業簡介

  • CSL
  • GRIFOLS
  • SHIRE
  • OCTAPHARMA
  • KEDRION
  • LFB
  • BIOTEST
  • SANQUIN
  • CHINA BIOLOGIC PRODUCTS
  • BIO PRODUCTS LABORATORY (BPL)
  • 日本血液製劑機構
  • GREEN CROSS CORPORATION
  • SHANGHAI RAAS BLOOD PRODUCTS

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH 4477

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma collection are the factors driving this market. However, the emergence of recombinant alternatives, high cost of plasma products, and limited reimbursement may hinder the growth of this market.

The protease inhibitors segment is expected to grow at the highest CAGR during the forecast period

On the basis of product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The protease inhibitors segment is expected to witness the highest growth during the forecast period. The high growth of this segment is primarily attributed to the increasing prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.

The pulmonology segment is projected to witness the highest growth during the forecast period

Based on the application, the plasma fractionation market is classified into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. The pulmonology segment

is expected to grow at the highest CAGR during the forecast period. This can largely be attributed to the increasing use of immunoglobulins and protease inhibitors in the treatment of various respiratory diseases such as AATD and COPD, asthma, and respiratory tract infections.

The hospitals and clinics segment is expected to grow at the highest CAGR during the forecast period

On the basis of type of end user, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. During the forecast period, the hospitals & clinics segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; large patient pool treated in hospitals; growing number of hospitals & clinics across the globe; and increasing number of collaborations between the manufacturers of plasma products and hospitals.

Asia Pacific to witness the highest growth during the forecast period

Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The region's large geriatric population, large population, improving healthcare infrastructure, increasing incidences of immunological and bleeding diseases, increasing focus diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products are driving the growth of this market.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-46%, Tier 2-33% and Tier 3-21%
  • By Designation - C Level-43%, Director Level-35%, Others-22%
  • By Region - North America-34%, Europe-26%, Asia Pacific-24%, Latin America-12%, Middle East and Africa- 4%

Some of the major market players in the plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).

Research Coverage:

The report analyzes the plasma fractionation market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a volume data analysis for various plasma products across the globe and a competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global plasma fractionation market. The report analyzes the global plasma fractionation market by product, application, end user, and region.
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global plasma fractionation market.
  • Market Development: Comprehensive information on the lucrative emerging markets by product, application, end user, and region.
  • Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global plasma fractionation market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the global plasma fractionation market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. SCOPE OF THE STUDY
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
    • 2.1.1. SECONDARY SOURCES
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY SOURCES
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
    • 2.2.1. BOTTOM-UP APPROACH
    • 2.2.2. TOP-DOWN APPROACH
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY
  • 2.6. LIMITATIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. PLASMA FRACTIONATION MARKET OVERVIEW
  • 4.2. ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018
  • 4.3. GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET
  • 4.4. PLASMA FRACTIONATION MARKET: REGIONAL MIX
  • 4.5. PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS. DEVELOPED COUNTRIES

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. MARKET DRIVERS
      • 5.2.1.1. Growing use of immunoglobulins in various therapeutic areas
      • 5.2.1.2. Rising geriatric population across the globe
      • 5.2.1.3. Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin
      • 5.2.1.4. Increase in plasma collection
    • 5.2.2. MARKET RESTRAINTS
      • 5.2.2.1. High cost and limited reimbursement
      • 5.2.2.2. Emergence of recombinant alternatives
    • 5.2.3. MARKET OPPORTUNITY
      • 5.2.3.1. Increasing number of hemophilia patients
    • 5.2.4. MARKET CHALLENGE
      • 5.2.4.1. Stringent government regulations

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. KEY INDUSTRY TRENDS
    • 6.2.1. FOCUS ON INCREASING FRACTIONATION CAPACITIES AND GEOGRAPHICAL EXPANSIONS
    • 6.2.2. NEW INDICATIONS FOR PLASMA PRODUCTS
    • 6.2.3. RISING ADOPTION OF SCIG
    • 6.2.4. INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS
    • 6.2.5. GROWING PLASMA PRODUCTS MARKET IN CHINA
    • 6.2.6. INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS
  • 6.3. PORTER'S FIVE FORCES
    • 6.3.1. THREAT FROM NEW ENTRANTS
    • 6.3.2. THREAT OF SUBSTITUTES
    • 6.3.3. BARGAINING POWER OF SUPPLIERS
    • 6.3.4. BARGAINING POWER OF BUYERS
    • 6.3.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.4. VENDOR BENCHMARKING

7. PLASMA FRACTIONATION MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. IMMUNOGLOBULIN
    • 7.2.1. INTRAVENOUS IMMUNOGLOBULIN (IVIG)
    • 7.2.2. SUBCUTANEOUS IMMUNOGLOBULIN (SCIG)
    • 7.2.3. OTHER IMMUNOGLOBULINS
  • 7.3. COAGULATION FACTOR CONCENTRATES
    • 7.3.1. FACTOR VIII
    • 7.3.2. FACTOR IX
    • 7.3.3. VON WILLEBRAND FACTOR
    • 7.3.4. PROTHROMBIN COMPLEX CONCENTRATE
    • 7.3.5. FIBRINOGEN CONCENTRATES
    • 7.3.6. FACTOR XIII
  • 7.4. ALBUMIN
  • 7.5. PROTEASE INHIBITORS
  • 7.6. OTHER PLASMA PRODUCTS

8. PLASMA FRACTIONATION MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. NEUROLOGY
  • 8.3. IMMUNOLOGY
  • 8.4. HEMATOLOGY
  • 8.5. CRITICAL CARE
  • 8.6. PULMONOLOGY
  • 8.7. HEMATO-ONCOLOGY
  • 8.8. RHEUMATOLOGY
  • 8.9. OTHER APPLICATIONS

9. PLASMA FRACTIONATION MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITALS & CLINICS
  • 9.3. CLINICAL RESEARCH LABORATORIES
  • 9.4. ACADEMIC INSTITUTES

10. GEOGRAPHIC ANALYSIS

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. ITALY
    • 10.3.4. SPAIN
    • 10.3.5. UK
    • 10.3.6. REST OF EUROPE
  • 10.4. ASIA PACIFIC
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. INDIA
    • 10.4.4. MALAYSIA
    • 10.4.5. REST OF ASIA PACIFIC
  • 10.5. LATIN AMERICA
  • 10.6. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SCENARIO AND TRENDS
    • 11.3.1. EXPANSIONS
    • 11.3.2. PRODUCT LAUNCHES
    • 11.3.3. ACQUISITIONS
    • 11.3.4. AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS

12. COMPANY PROFILES (Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*

  • 12.1. CSL
  • 12.2. GRIFOLS
  • 12.3. SHIRE
  • 12.4. OCTAPHARMA
  • 12.5. KEDRION
  • 12.6. LFB
  • 12.7. BIOTEST
  • 12.8. SANQUIN
  • 12.9. CHINA BIOLOGIC PRODUCTS
  • 12.10. BIO PRODUCTS LABORATORY (BPL)
  • 12.11. JAPAN BLOOD PRODUCTS ORGANIZATION
  • 12.12. GREEN CROSS CORPORATION
  • 12.13. SHANGHAI RAAS BLOOD PRODUCTS

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. AVAILABLE CUSTOMIZATION
  • 13.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.6. RELATED REPORT
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS
  • TABLE 2: ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
  • TABLE 3: NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION, 2017
  • TABLE 4: INCREASE IN GERIATRIC POPULATION FROM 2000 TO 2050 ACROSS THE GLOBE
  • TABLE 5: NUMBER OF PLASMA COLLECTION CENTERS (2017)
  • TABLE 6: NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016
  • TABLE 7: CHARACTERISTICS OF PLASMA FOR FRACTIONATION
  • TABLE 8: FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYER
  • TABLE 9: PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2014)
  • TABLE 10: CHINA:TOP PLAYERS IN ALBUMIN MARKET, 2017
  • TABLE 11: MAJOR LOCAL PLAYERS IN CHINA
  • TABLE 12: REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON PLASMA-DERIVED PRODUCTS
  • TABLE 13: PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET
  • TABLE 14: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 15: IMMUNOGLOBULIN MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 16: IMMUNOGLOBULIN MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 2016-2023 (METRIC TONS)
  • TABLE 18: INTRAVENOUS IMMUNOGLOBULIN OFFERED BY KEY MARKET PLAYERS
  • TABLE 19: IVIG MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 20: IVIG MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • TABLE 21: COMPARISON OF PROS AND CONS, IVIG VS SCIG THERAPY
  • TABLE 22: SCIG OFFERED BY KEY MARKET PLAYERS
  • TABLE 23: SCIG MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 24: OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
  • TABLE 25: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 26: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 27: COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 28: FACTOR VIII OFFERED BY KEY MARKET PLAYERS
  • TABLE 29: GLOBAL FACTOR VIII MARKET, BY REGION, 2016-2023 (MILLION INTERNATIONAL UNITS)
  • TABLE 30: FACTOR VIII MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 31: FACTOR VIII MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • TABLE 32: FACTOR IX OFFERED BY KEY MARKET PLAYERS
  • TABLE 33: FACTOR IX MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 34: VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
  • TABLE 35: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 36: PROTHROMBIN COMPLEX CONCENTRATE OFFERED BY KEY MARKET PLAYERS
  • TABLE 37: PROTHROMBIN COMPLEX CONCENTRATE MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 38: FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
  • TABLE 39: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 40: FACTOR XIII OFFERED BY KEY MARKET PLAYERS
  • TABLE 41: FACTOR XIII MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 42: ALBUMIN OFFERED BY KEY MARKET PLAYERS
  • TABLE 43: ALBUMIN MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 44: GLOBAL ALBUMIN MARKET, BY REGION, 2016-2023 (METRIC TONS)
  • TABLE 45: PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
  • TABLE 46: PROTEASE INHIBITORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 47: OTHER PLASMA PRODUCTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 48: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 49: NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND A PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
  • TABLE 50: PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN NEUROLOGY
  • TABLE 51: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 52: LIST OF FDA APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
  • TABLE 53: PREVALENCE OF PID, BY REGION, 2013 VS. 2015
  • TABLE 54: PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN IMMUNOLOGY
  • TABLE 55: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 56: NUMBER OF HEMOPHILIC PATIENTS (2012-2016)
  • TABLE 57: PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN HEMATOLOGY
  • TABLE 58: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 59: PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN CRITICAL CARE
  • TABLE 60: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 61: PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN PULMONOLOGY
  • TABLE 62: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 63: ESTIMATED CANCER INCIDENCE, BY REGION, 2012 VS. 2015
  • TABLE 64: PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN HEMATO-ONCOLOGY
  • TABLE 65: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 66: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 67: PLASMA-DERIVED PRODUCTS AND ITS OTHER APPLICATIONS
  • TABLE 68: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 69: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 70: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 71: CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN (2017)
  • TABLE 72: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 73: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 74: NUMBER OF PLASMA FRACTIONATION PLANTS, BY REGION, 2014
  • TABLE 75: PLASMA FRACTIONATION MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 76: NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2016
  • TABLE 77: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 78: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 79: NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 80: NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 81: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 82: NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 83: US: NUMBER OF PLASMA DONATIONS & PLASMA DONATION CENTERS
  • TABLE 84: US: KEY MACROINDICATORS
  • TABLE 85: US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 86: US: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 87: US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 88: US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 89: US: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 90: CANADA: KEY MACROINDICATORS
  • TABLE 91: CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 92: CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 93: CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 94: CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 95: CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 96: EUROPE: NUMBER OF PLASMA DONATION CENTERS
  • TABLE 97: PLASMA FRACTIONATION PLANTS IN EUROPE (2017)
  • TABLE 98: EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 99: EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 100: EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 101: EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 102: EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 103: EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 104: GERMANY: KEY MACROINDICATORS
  • TABLE 105: GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 106: GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 107: GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 108: GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 109: GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 110: NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE: 2012-2016
  • TABLE 111: FRANCE: KEY MACROINDICATORS
  • TABLE 112: FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 113: FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 114: FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 115: FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 116: FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 117: ITALY: NUMBER OF BLOOD DONATIONS, 2011 VS. 2013
  • TABLE 118: PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013)
  • TABLE 119: ITALY: KEY MACROINDICATORS
  • TABLE 120: ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 121: ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 122: ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 123: ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 124: ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 125: SPAIN: KEY MACROINDICATORS
  • TABLE 126: SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 127: SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 128: SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 129: SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 130: SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 131: USAGE OF IMMUNOGLOBULINS
  • TABLE 132: ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS IN THE UK, 2012-2016
  • TABLE 133: UK: KEY MACROINDICATORS
  • TABLE 134: UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 135: UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 136: UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 137: UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 138: UK: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 139: TOTAL NUMBER OF HEMOPHILIA PATIENTS IN THE ROE: 2012-2016
  • TABLE 140: ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 141: ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 142: ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 143: ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 144: ROE: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 145: APAC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 146: APAC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 147: APAC: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 148: APAC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 149: APAC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 150: APAC: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 151: CHINA: KEY MACROINDICATORS
  • TABLE 152: CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 153: CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 154: CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 155: CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 156: CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 157: JAPAN: KEY MACROINDICATORS
  • TABLE 158: JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 159: JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 160: JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 161: JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 162: JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 163: INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS: 2012-2016
  • TABLE 164: INDIA: KEY MACROINDICATORS
  • TABLE 165: INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 166: INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 167: INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 168: INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 169: INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 170: MALAYSIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS: 2012-2016
  • TABLE 171: MALAYSIA: KEY MACROINDICATORS
  • TABLE 172: MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 173: MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 174: MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD THOUSAND)
  • TABLE 175: MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 176: MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 177: ROAPAC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 178: ROAPAC: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 179: ROAPAC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 180: ROAPAC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 181: ROAPAC: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 182: LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 183: LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 184: LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 185: LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 186: LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 187: HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA: 2012-2016
  • TABLE 188: PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION: 2012-2016)
  • TABLE 189: MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 190: MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 191: MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 192: MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 193: MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 194: EXPANSIONS, JANUARY 2014 TO DECEMBER 2017
  • TABLE 195: PRODUCT LAUNCHES, JANUARY 2014 TO DECEMBER 2017
  • TABLE 196: ACQUISITIONS, JANUARY 2014 TO DECEMBER 2017
  • TABLE 197: AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2014 TO DECEMBER 2017

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION METHODOLOGY
  • FIGURE 4: IMMUNOGLOBULINS SEGMENT TO DOMINATE THE PLASMA FRACTIONATION MARKET, BY PRODUCT, DURING 2018 TO 2023
  • FIGURE 5: NEUROLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 6: PLASMA FRACTIONATION MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
  • FIGURE 7: GEOGRAPHIC SNAPSHOT: PLASMA FRACTIONATION MARKET IN 2017
  • FIGURE 8: GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
  • FIGURE 9: ALBUMIN ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2017
  • FIGURE 10: THE US ACCOUNTED FOR THE LARGEST SHARE OF THE PLASMA FRACTIONATION MARKET IN 2017
  • FIGURE 11: ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 12: DEVELOPING COUNTRIES TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 13: COPD AND ASTHMA PREVALENCE, BY COUNTRY, 2015
  • FIGURE 14: GLOBAL PERCENTAGE OF DEATHS FROM RESPIRATORY DISEASES, 2008 TO 2030
  • FIGURE 15: PLASMA COLLECTION IN EUROPE, 2005-2013
  • FIGURE 16: SOURCE PLASMA COLLECTION IN THE US, 2007-2016
  • FIGURE 17: NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012-2016
  • FIGURE 18: INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS
  • FIGURE 19: PLASMA FRACTIONATION MARKET IN CHINA VS. DEVELOPED COUNTRIES, 2018 VS 2023
  • FIGURE 20: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 21: IMMUNOGLOBULIN MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 22: ESTIMATED LIFETIME RISK OF ALZHEIMER'S DISEASE, BY AGE & SEX (2016)
  • FIGURE 23: PREVALENCE OF DIFFERENT BLEEDING DISORDERS, BY COUNTRY, 2016
  • FIGURE 24: COAGULATION FACTOR MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 25: MEAN PER CAPITA USAGE OF FACTOR VIII (2016)
  • FIGURE 26: MEAN PER CAPITA USAGE OF FACTOR IX (2016)
  • FIGURE 27: ALBUMIN MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 28: NEUROLOGY SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2018 TO 2023
  • FIGURE 29: NUMBER OF HEMOPHILIA PATIENTS IN MAJOR COUNTRIES, 2016
  • FIGURE 30: HOSPITALS & CLINICS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 31: PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 32: NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 33: NORTH AMERICA: PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 34: PLASMA COLLECTION VOLUME IN THE US, 2007-2016
  • FIGURE 35: PLASMA COLLECTION CENTERS IN THE US, 2005-2016
  • FIGURE 36: US: PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 37: EUROPE: PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 38: EUROPE: PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 39: HEMOPHILIA A & B PATIENTS IN GERMANY, 2013-2016
  • FIGURE 40: APAC: PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 41: KEY STRATEGIES ADOPTED BY PLAYERS (JAN 2014-DECEMBER 2017)
  • FIGURE 42: GLOBAL PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 43: CSL: COMPANY SNAPSHOT (2017)
  • FIGURE 44: GRIFOLS: COMPANY SNAPSHOT (2016)
  • FIGURE 45: SHIRE: COMPANY SNAPSHOT (2016)
  • FIGURE 46: OCTAPHARMA: COMPANY SNAPSHOT (2016)
  • FIGURE 47: KEDRION: COMPANY SNAPSHOT (2016)
  • FIGURE 48: LFB: COMPANY SNAPSHOT (2016)
  • FIGURE 49: BIOTEST: COMPANY SNAPSHOT (2016)
  • FIGURE 50: SANQUIN: COMPANY SNAPSHOT (2015)
  • FIGURE 51: CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2016)
  • FIGURE 52: JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2016)
  • FIGURE 53: GREEN CROSS CORPORATION: COMPANY SNAPSHOT (2016)
Back to Top